Median adjusted scores of the control and Col1a2-Foxf2-TRAMP mouse prostate cancers were 30 and 22, respectively and were statistically different (Fig. 3c), supporting a delayed disease progression in the Col1a2-Foxf2-TRAMP group. This evidence concerns the gene FOXF2 and prostate cancer.